These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 23084806)

  • 1. After six months of anti-psychotic treatment: Is the improvement in mental health at the expense of physical health?
    Martín Otaño L; Barbadillo Izquierdo L; Galdeano Mondragón A; Alonso Pinedo M; Querejeta Ayerdi I
    Rev Psiquiatr Salud Ment; 2013; 6(1):26-32. PubMed ID: 23084806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
    Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
    Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic syndrome in patients with psychotic disorders: diagnostic issues, comorbidity and side effects of antipsychotics.
    Kozumplik O; Uzun S; Jakovljević M
    Psychiatr Danub; 2010 Mar; 22(1):69-74. PubMed ID: 20305594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic syndrome in female patients with schizophrenia treated with second generation antipsychotics: a 3-month follow-up.
    Medved V; Kuzman MR; Jovanovic N; Grubisin J; Kuzman T
    J Psychopharmacol; 2009 Nov; 23(8):915-22. PubMed ID: 18635691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic syndrome and cardiovascular risk among patients with schizophrenia receiving antipsychotics in Malaysia.
    Said MA; Sulaiman AH; Habil MH; Das S; Bakar AK; Yusoff RM; Loo TH; Bakar SA
    Singapore Med J; 2012 Dec; 53(12):801-7. PubMed ID: 23268153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of the metabolic syndrome in schizophrenic patients receiving second-generation antipsychotic agents--a cross-sectional study.
    Kagal UA; Torgal SS; Patil NM; Malleshappa A
    J Pharm Pract; 2012 Jun; 25(3):368-73. PubMed ID: 22551560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Easy and low-cost identification of metabolic syndrome in patients treated with second-generation antipsychotics: artificial neural network and logistic regression models.
    Lin CC; Bai YM; Chen JY; Hwang TJ; Chen TT; Chiu HW; Li YC
    J Clin Psychiatry; 2010 Mar; 71(3):225-34. PubMed ID: 19814949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ziprasidone's effect on metabolic markers in patients with diabetes and chronic schizophrenia.
    Lindenmayer JP; Tedeschi F; Yusim A; Khan A; Kaushik S; Smith RC; Parakadavil M
    Clin Schizophr Relat Psychoses; 2012 Jan; 5(4):185-92. PubMed ID: 22182455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MTHFR genotype and differential evolution of metabolic parameters after initiation of a second generation antipsychotic: an observational study.
    van Winkel R; Moons T; Peerbooms O; Rutten B; Peuskens J; Claes S; van Os J; De Hert M
    Int Clin Psychopharmacol; 2010 Sep; 25(5):270-6. PubMed ID: 20523222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme.
    Poulin MJ; Chaput JP; Simard V; Vincent P; Bernier J; Gauthier Y; Lanctôt G; Saindon J; Vincent A; Gagnon S; Tremblay A
    Aust N Z J Psychiatry; 2007 Dec; 41(12):980-9. PubMed ID: 17999270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of a 10-week weight control program on obese patients with schizophrenia or schizoaffective disorder: a 12-month follow up.
    Chen CK; Chen YC; Huang YS
    Psychiatry Clin Neurosci; 2009 Feb; 63(1):17-22. PubMed ID: 19067997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
    Citrome L; Meng X; Hochfeld M; Stahl SM
    Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic risk status and second-generation antipsychotic drug selection: a retrospective study of commercially insured patients.
    Morrato EH; Cuffel B; Newcomer JW; Lombardo I; Kamat S; Barron J
    J Clin Psychopharmacol; 2009 Feb; 29(1):26-32. PubMed ID: 19142103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of adjunctive metformin on metabolic traits in nondiabetic clozapine-treated patients with schizophrenia and the effect of metformin discontinuation on body weight: a 24-week, randomized, double-blind, placebo-controlled study.
    Chen CH; Huang MC; Kao CF; Lin SK; Kuo PH; Chiu CC; Lu ML
    J Clin Psychiatry; 2013 May; 74(5):e424-30. PubMed ID: 23759461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic issues in psychotic disorders with the focus on first-episode patients: a review.
    Britvic D; Maric NP; Doknic M; Pekic S; Andric S; Jasovic-Gasic M; Popovic V
    Psychiatr Danub; 2013 Dec; 25(4):410-5. PubMed ID: 24247054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effective screening for the metabolic syndrome in patients treated with second-generation antipsychotic medications.
    Straker D; Correll CU; Kramer-Ginsberg E; Abdulhamid N; Koshy F; Rubens E; Saint-Vil R; Kane JM; Manu P
    Am J Psychiatry; 2005 Jun; 162(6):1217-21. PubMed ID: 15930076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effectiveness of switching antipsychotic drug treatment to aripiprazole or ziprasidone for improving metabolic profile and atherogenic dyslipidemia: a 12-month, prospective, open-label study.
    Chen Y; Bobo WV; Watts K; Jayathilake K; Tang T; Meltzer HY
    J Psychopharmacol; 2012 Sep; 26(9):1201-10. PubMed ID: 22234928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prevalence of metabolic syndrome and its association with alanine aminotransferase in clozapine-treated Korean patients with schizophrenia.
    Lee NY; Roh MS; Kim SH; Jung DC; Yu HY; Sung KH; Chung IW; Youn T; Kang UG; Ahn YM; Kim YS
    Int Clin Psychopharmacol; 2013 Mar; 28(2):71-9. PubMed ID: 23211493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prevalence of the metabolic syndrome in patients with schizoaffective disorder--bipolar subtype.
    Basu R; Brar JS; Chengappa KN; John V; Parepally H; Gershon S; Schlicht P; Kupfer DJ
    Bipolar Disord; 2004 Aug; 6(4):314-8. PubMed ID: 15225149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.